Most people around the world are infected at some point with the Epstein Barr virus, or EBV. It usually causes mild illness or no symptoms at all and then stays quietly in the body for life. Yet in a small number of people, EBV is linked to cancers such as nasopharyngeal cancer. Scientists have long wondered why the same virus leads to very different outcomes.
New research suggests the answer lies in a precise match between the virus and a person’s genetic makeup. Instead of looking only at human genes or only at the virus, researchers studied both together. They found that certain versions of human immune genes interact with specific versions of EBV in a way that makes it harder for the body to recognize and control infected cells.
One key finding involves a gene called HLA A, which helps the immune system display pieces of viruses to immune cells. In some individuals, a particular form of this gene does not present certain EBV proteins as effectively. When this human gene variant is paired with a specific EBV variant, the virus can better evade immune detection. Over time, this may increase the chance that infected cells grow uncontrollably and develop into cancer.
This discovery matters because it shifts how we think about risk. It is not just about being infected with EBV, which is very common. It is about the combination of your genes and the exact strain of the virus you carry. In the future, this knowledge could help doctors identify people at higher risk and monitor them more closely. It may also guide the development of vaccines or treatments that are tailored to these high risk combinations.
For now, the takeaway is simple. A common virus can behave very differently depending on who it infects, and understanding that interaction brings us closer to more personalized and effective prevention.
References
Chen, Y., Liang, J., Zhang, W. et al. EBV strain interacts with host HLA to drive nasopharyngeal carcinoma risk. Nature (2026). https://doi.org/10.1038/s41586-026-10416-8
